申请人:Hoffmann-La Roche Inc.
公开号:US06225316B1
公开(公告)日:2001-05-01
The invention relates to compounds of the formula
wherein
R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;
R1 is hydrogen or halogen; or
R and R1 may be together —CH═CH—CH═CH—;
R2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;
R3 is hydrogen, lower alkyl or form a cycloalkyl group;
R4 is hydrogen, —N(R5)2, —N(R5)S(O)2-lower alkyl, —N(R5)C(O)R5 or a cyclic tertiary amine of the group
R5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl;
R6 is hydrogen, hydroxy, lower alkyl, —N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, —CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group,
X is —C(O)N(R5)—, —(CH2)mO—, —(CH2)mN(R5)—, —N(R5)C(O)—, or —N(R5)(CH2)m—;
n is 0-4; and
m is 1 or 2;
and to pharmaceutically acceptable acid addition salts thereof.
It has been shown that the above mentioned compounds have a good affinity to the NK-1 receptor.
本发明涉及以下式子的化合物:其中R为氢、低级烷基、低级烷氧基、卤素或三氟甲基;R1为氢或卤素;或R和R1可以一起为—CH═CH—CH═CH—;R2为氢、卤素、三氟甲基、低级烷氧基或氰基;R3为氢、低级烷基或形成环烷基;R4为氢、—N(R5)2、—N(R5)S(O)2-低级烷基、—N(R5)C(O)R5或R5为群体的环状三级胺,其中R5独立地为氢、C3-6环烷基、苄基或低级烷基;R6为氢、羟基、低级烷基、—N(R5)CO-低级烷基、羟基-低级烷基、氰基、—CHO或5-或6-成员杂环基,可选择通过烷基链连接;X为—C(O)N(R5)—、—(CH2)mO—、—(CH2)mN(R5)—、—N(R5)C(O)—或—N(R5)(CH2)m—;n为0-4;m为1或2;以及其药物可接受的酸加成盐。已经证明,上述化合物对NK-1受体具有良好的亲和力。